衣康酸抑制CD103+组织驻留记忆T细胞并减轻原发性硬化性胆管炎小鼠模型的肝胆损伤
研究评估了原发性硬化性胆管炎(PSC)患者肝内CD103+组织驻留记忆T细胞(TRM)增多且与疾病严重程度正相关,血清衣康酸水平降低;体外4-辛基衣康酸(4-OI)抑制CD103+ TRM的诱导和效应功能,机制涉及阻断CD8+ T细胞中RUNX3的DNA去甲基化;小鼠模型中4-OI减少肝内CD103+ TRM并改善肝损伤。
要点
- PSC患者肝内CD103+ TRM显著扩增,且与疾病严重程度正相关。
- PSC患者血清衣康酸水平降低。
- 4-OI在体外抑制CD103+ TRM诱导和效应功能,并阻断CD8+ T细胞RUNX3 DNA去甲基化。
核心结论
- 衣康酸在体外和小鼠PSC模型中对CD103+ TRM发挥免疫调节活性,靶向致病性CD103+ TRM可能对PSC具有治疗潜力。
研究设计与样本
- 研究纳入PSC患者(n=32)评估肝内CD103+ TRM数量,PSC(n=64)、原发性胆汁性胆管炎(n=60)、自身免疫性肝炎(n=49)和健康对照(n=109)检测血清衣康酸水平。
- 使用PSC(n=5)和健康供者(n=6)的肝组织外植体通过流式细胞术定量肝内TRM频率和免疫表型。
- 体外研究4-OI对CD103+ TRM的免疫调节作用,并在小鼠PSC模型中通过给予4-OI和免疫反应基因1缺陷研究衣康酸的治疗潜力。
主要发现
- PSC患者肝内CD103+ TRM显著扩增,且与疾病严重程度正相关。
- PSC患者血清衣康酸水平降低。
- 4-OI在体外抑制CD103+ TRM的诱导和效应功能,并阻断CD8+ T细胞中RUNX3的DNA去甲基化。
- 4-OI减少小鼠PSC模型肝内CD103+ TRM并改善肝损伤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease characterized by the infiltration of intrahepatic tissue-resident memory CD8 + T cells (T RM ). Itaconate has demonstrated therapeutic potential in modulating inflammation. An unmet need for PSC is the reduction of biliary inflammation, and we hypothesized that itaconate may directly modulate pathogenic T RM . APPROACH AND RESULTS: The numbers of intrahepatic CD103 + T RM were evaluated by immunofluorescence in PSC (n = 32), and the serum levels of itaconate in PSC (n = 64), primary biliary cholangitis (PBC) (n = 60), autoimmune hepatitis (AIH) (n = 49), and healthy controls (n = 109) were determined by LC-MS/MS. In addition, the frequencies and immunophenotypes of intrahepatic T RM using explants from PSC (n = 5) and healthy donors (n = 6) were quantitated by flow cytometry. The immunomodulatory properties of 4-octyl itaconate (4-OI, a cell-permeable itaconate derivative) on CD103 + T RM were studied in vitro. Finally, the therapeutic potential of itaconate was studied by the administration of 4-OI and deficiency of immune-responsive gene 1 (encodes the aconitate decarboxylase producing itaconate) in murine models of PSC. Intrahepatic CD103 + T RM was significantly expanded in PSC and was positively correlated with disease severity. Serum itaconate levels decreased in PSC. Importantly, 4-OI inhibited the induction and effector functions of CD103 + T RM in vitro. Mechanistically, 4-OI blocked DNA demethylation of RUNX3 in CD8 + T cells. Moreover, 4-OI reduced intrahepatic CD103 + T RM and ameliorated liver injury in murine models of PSC. CONCLUSIONS: Itaconate exerted immunomodulatory activity on CD103 + T RM in both in vitro and murine PSC models. Our study suggests that targeting pathogenic CD103 + T RM with itaconate has therapeutic potential in PSC.
引用
- Li Y, Li B, Xiao X, et al. Itaconate inhibits CD103 + T RM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis. Hepatology. 2023. PMID: 37505225. doi:10.1097/HEP.0000000000000549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。